Actinium Pharmaceuticals (ATNM) Competitors

Innate Pharma (NASDAQ:IPHA) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Is IPHA or ATNM more profitable?

Innate Pharma's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Which has preferable earnings & valuation, IPHA or ATNM?

Actinium Pharmaceuticals has lower revenue, but higher earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$21.77M	7.38	-$53.53M	N/A	N/A
Actinium Pharmaceuticals	N/A	N/A	-$48.82M	-$1.47	-1.03

Which has more volatility and risk, IPHA or ATNM?

Innate Pharma has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.32, indicating that its share price is 132% less volatile than the S&P 500.

Do analysts recommend IPHA or ATNM?

Innate Pharma currently has a consensus target price of $11.00, suggesting a potential upside of 531.02%. Actinium Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 163.16%. Given Innate Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Innate Pharma is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Actinium Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Does the media prefer IPHA or ATNM?

In the previous week, Innate Pharma and Innate Pharma both had 1 articles in the media. Innate Pharma's average media sentiment score of 1.89 beat Actinium Pharmaceuticals' score of 1.14 indicating that Innate Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Innate Pharma	Very Positive
Actinium Pharmaceuticals	Positive

Do institutionals & insiders have more ownership in IPHA or ATNM?

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Innate Pharma beats Actinium Pharmaceuticals on 9 of the 12 factors compared between the two stocks.